Inactive Instrument

ADVANCED LIFE SCIE Share Price Other OTC

Equities

Pharmaceuticals

End-of-day quote Other OTC
- USD - Intraday chart for ADVANCED LIFE SCIE
Sales 2009 27.93L 23Cr Sales 2010 8L 6.28Cr Capitalization 90.76L 76Cr
Net income 2009 -90L -75Cr Net income 2010 -90L -75Cr EV / Sales 2009 8.04 x
Net Debt 2009 91.63L 76Cr Net Debt 2010 79.41L 66Cr EV / Sales 2010 22.6 x
P/E ratio 2009
-1.05 x
P/E ratio 2010
-0.57 x
Employees -
Yield 2009 *
-
Yield 2010
-
Free-Float 84.42%
More Fundamentals * Assessed data
Advanced Life Sciences Holdings, Inc. is a United States-based biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of drugs in the therapeutic areas of infection, cancer, and respiratory diseases. The Company’s Restanza is an antibiotic in development for the treatment of life-threatening infections including community-acquired bacterial pneumonia and biodefense pathogens including anthrax, plague, and tularemia. Its ALS-886 is a therapeutic molecule in preclinical studies is being developed for the treatment intended to reduce and prevent the tissue damage associated with diseases such as Adult Respiratory Distress Syndrome (ARDS). Its ALS-357 is a natural product in preclinical studies has demonstrated specific anti-tumor activity against malignant melanoma. Preclinical studies have shown that direct injection of ALS-357 into grafted human tumors induced apoptosis, programmed cell death, within the tumors.
More about the company